NICE NG220: multiple sclerosis in adults
International NICE Current
Multiple sclerosis in adults: management (NG220)
National Institute for Health and Care Excellence. NG220, June 2022 (last updated 2026)
Summary checked against the source: 2026-11
NICE NG220 (June 2022) covers diagnosis, information and support, symptom management, relapse and disease-modifying therapy. It was amended in 2026 to point to the 2024 revised McDonald criteria and to list newer technology appraisals. NICE strength is in the wording: offer = strong, consider = weaker. Citations give the recommendation number.
At a glance
- Typical presentations: monocular visual loss with painful eye movements, diplopia, ascending sensory disturbance or weakness, Lhermitte's sign, progressive gait or balance problems. [1.1.1]
- Usually under 50, symptoms evolving over >24 h, lasting days to weeks then improving, no fever or infection. [1.1.2]
- Diagnosis: consultant neurologist, using history, examination, MRI and labs with the 2024 McDonald criteria. [1.1.5–1.1.6]
- Relapse = new or worse symptoms >24 h, after ≥1 month of stability, with no infection. Treat within 14 days with oral methylprednisolone 0.5 g daily for 5 days. [1.7.1, 1.7.5, 1.7.7]
- Spasticity: baclofen first, gabapentin second. Oscillopsia: gabapentin, then memantine. Fatigue: self-management and exercise; amantadine, modafinil or an SSRI only after specialist discussion. [1.5]
- Disease-modifying therapy follows NICE technology appraisals. Siponimod for active secondary progressive MS; ocrelizumab for early active primary progressive MS. [1.8]
- Not recommended: vitamin D solely to treat MS, omega-3 or omega-6 supplements, hyperbaric oxygen for fatigue. [1.9.1–1.9.2, 1.5.11]
Diagnosis
Recognising and referring [1.1]
- Don't routinely suspect MS when the main symptoms are fatigue, depression, dizziness or vague sensory symptoms without focal signs. [1.1.3]
- Before referring, confirm it's a neurological episode and exclude commoner diagnoses. [1.1.4]
- Diagnosis by a consultant neurologist, using the 2024 revised McDonald criteria. [1.1.5–1.1.6]
- Clinically isolated syndrome, or suspected MS not meeting McDonald: plan review (e.g. yearly) and make sure the person knows whom to contact. [1.1.7]
- Isolated optic neuritis confirmed by an ophthalmologist: refer to a neurologist. NMOSD is diagnosed by a specialist on current criteria. [1.1.9–1.1.10]
Living with MS
- Single point of contact and a coordinated multidisciplinary team. [1.3]
- Exercise is beneficial and doesn't harm MS. Stop smoking: it speeds disability progression. Vaccinate per national schedules. [1.4.1–1.4.3]
- Comprehensive review at least once a year, covering MS symptoms, general health, activities, social care and carers. [1.6]
- Discuss pregnancy plans early: some DMTs need planning before conception. [1.2]
Symptom management
| Symptom | Management | Wording |
|---|---|---|
| Fatigue | Look for other causes (sleep problems, pain, spasticity, bladder symptoms, drugs, infection, anaemia, thyroid, anxiety, depression). Self-management discussion; aerobic, resistance and balance exercise, yoga | Offer / advise |
| EDSS ≥4: supervised aerobic and moderate progressive resistance exercise plus cognitive behavioural techniques | Consider | |
| Medicines (specialist decision): amantadine, modafinil (not in pregnancy), SSRI | Consider | |
| Hyperbaric oxygen; vitamin B12 injections | Do not offer / do not use | |
| Mobility | Assessment with rehabilitation specialists and physiotherapists; vestibular rehabilitation for poor standing balance | Ensure / consider |
| Spasticity | Look for aggravating factors (pressure sores, bladder or bowel problems, infection, posture, pain). Some people need their spasticity to stand or transfer | Assess |
| 1st line: oral baclofen | Consider | |
| 2nd line: gabapentin, or baclofen + gabapentin combined | Consider | |
| Titrate in ≥2-week steps; don't stop baclofen suddenly. Refractory: refer to a spasticity MDT; THC:CBD spray per NICE NG144 | ||
| Oscillopsia | 1st line gabapentin, 2nd line memantine | Consider |
| Emotional lability | Amitriptyline | Consider |
| Pain | Neuropathic pain per NICE's neuropathic pain guideline; musculoskeletal pain is usually secondary to posture or mobility | Treat / refer |
| Cognition | Assess at each review; consider neuropsychology referral | Consider |
Adapted from NICE NG220 section 1.5
Relapse
flowchart TD
A["New or worsening symptoms<br/>>24 h, after ≥1 month stable"] --> B{"Infection or other cause?<br/>(especially UTI, chest)"}
B -->|Yes| C["Treat the cause:<br/>not a relapse"]
B -->|No| D{"Symptoms present<br/>>3 months?"}
D -->|Yes| E["Don't routinely diagnose relapse:<br/>think fluctuation or progression"]
D -->|No| F["Relapse affecting usual tasks:<br/>assess and treat within 14 days"]
F --> G["Oral methylprednisolone<br/>0.5 g daily for 5 days"]
F --> H["IV methylprednisolone 1 g daily for 3–5 days if<br/>oral steroids failed or not tolerated,<br/>or admitted for severe relapse or comorbidity"]
Built from NICE NG220 recommendations 1.7.1–1.7.9; NICE has no figure for this.
Do not [1.7]
- Lower steroid doses than methylprednisolone 0.5 g daily for 5 days.
- Give people a supply of steroids to keep at home for future relapses.
- Explain steroid side effects: insomnia, mood change, confusion, worse glucose control in diabetes. [1.7.12]
Disease-modifying therapy
| Disease type | NICE-appraised options |
|---|---|
| Active relapsing–remitting | Interferon beta-1a, peginterferon beta-1a, glatiramer acetate, teriflunomide, dimethyl or diroximel fumarate, ponesimod, ofatumumab, ocrelizumab, ublituximab, cladribine |
| Highly active RRMS (activity despite treatment) | Natalizumab (SC or IV biosimilar), alemtuzumab, cladribine, fingolimod, ocrelizumab, ofatumumab, ublituximab, ponesimod |
| Rapidly evolving severe RRMS | Natalizumab, alemtuzumab, cladribine, ocrelizumab, ofatumumab, ublituximab; fingolimod if at high risk of PML |
| Active secondary progressive | Siponimod; interferon beta-1b |
| Early primary progressive with inflammatory activity on imaging | Ocrelizumab |
| Not recommended | Ozanimod; interferon beta-1b (Betaferon) for RRMS; natalizumab IV originator for highly active RRMS |
Adapted from NICE NG220 section 1.8 (updated with appraisals to January 2026)
Clinical pearls
- Uhthoff's phenomenon: symptoms worsen with heat or exercise. Lhermitte's sign: electric shock down the spine on neck flexion.
- Relapse: rule out UTI first. Steroids speed recovery but don't change long-term disability.
- Natalizumab carries the risk of PML (JC virus); fingolimod is an alternative when that risk is high.
- Ocrelizumab (anti-CD20) is the only NICE-approved option for primary progressive MS.
Classes and levels of evidence
How NICE NG220 2022 grades its recommendations. Adapted from NICE NG220 2022 None [None]. Hover over any class or level cited on this page to see what it means.
| Wording | Meaning |
|---|---|
| Offer / Refer / Advise / Do not … | Strong recommendation: the committee is confident that, for most people, the intervention will do more good than harm (or, for "do not", more harm than good) |
| Consider | Weaker recommendation: the benefit is less certain, and more people would choose not to have it; discuss options with the person |
| Must / Must not | Legal duty, or the consequences of not following it could be extremely serious |
NICE doesn't label recommendations with classes or levels of evidence. Its wording carries the strength instead, and the year in brackets after each recommendation shows when it was last reviewed. Citations on this page give the recommendation number.